Positron emission tomography (PET) imaging of the C-X-C chemokine receptor 4 (CXCR4) with [Ga]PentixaFor has intrinsic diagnostic value and is used to select patients for personalized CXCR4-targeted radionuclide therapy with its therapeutic radiopharmaceutical companion [Lu]PentixaTher. However, a CXCR4-targeting radiopharmaceutical labeled with fluorine-18 is still of high value due to its favorable characteristics over gallium-68. Furthermore, clinical results with [Lu]PentixaTher are promising, but there is still room for improvement regarding pharmacokinetics and dosimetry profile. Therefore, this study aimed to develop innovative CXCR4-targeting radiopharmaceuticals, both for diagnostic and therapeutic purposes, starting from a D-amino acid-based peptide probe (DV1-k-(DV3)) that conserves high CXCR4 binding affinity after radiolabeling. AlF-NOTA-DV1-k-(DV3) showed similar in vitro binding affinity to human CXCR4 (hCXCR4) compared to [Ga]PentixaFor (half-maximal inhibitory concentration (IC): 5.3 ± 0.9 nM and 8.6 ± 1.1 nM, respectively) and also binds to murine CXCR4 (mCXCR4) (IC: 33.4 ± 13.5 nM) while [Ga]PentixaFor is selective for hCXCR4 (IC > 1000 nM for mCXCR4). Both the diagnostic radiotracers based on the DV1-k-(DV3) vector platform, [F]AlF-NOTA-DV1-k-(DV3) and [Ga]Ga-DOTA-DV1-k-(DV3), and their therapeutic companion [Lu]Lu-DOTA-DV1-k-(DV3) were successfully produced in high yield, demonstrated high in vitro and in vivo stability, and have the same favorable pharmacokinetic profile. Furthermore, in wild-type mice and a hCXCR4-expressing tumor model, [F]AlF-NOTA-DV1-k-(DV3) shows CXCR4-specific targeting in mCXCR4-expressing organs such as liver (mean standardized uptake value (SUV) 8.2 ± 1.0 at 75 min post-injection (p.i.)), spleen (SUV 2.5 ± 1.0 at 75 min p.i.), and bone (SUV 0.4 ± 0.1 at 75 min p.i., femur harboring bone marrow) that can be blocked with the CXCR4 antagonist AMD3100. However, in a hCXCR4-expressing tumor model, tumor uptake of [F]AlF-NOTA-DV1-k-(DV3) was significantly lower (SUV 0.6 ± 0.2) compared to [Ga]PentixaFor (SUV 2.9). This might be explained by the high affinity of [F]AlF-NOTA-DV1-k-(DV3) toward both mCXCR4 and hCXCR4. High mCXCR4 expression in mouse liver results in a large fraction of [F]AlF-NOTA-DV1-k-(DV3) that is sequestered to the liver, resulting despite its similar in vitro affinity for hCXCR4, in lower tumor accumulation compared to [Ga]PentixaFor. As CXCR4 is not expressed in healthy human liver, the findings in mice are not predictive for the potential clinical performance of this novel class of CXCR4-targeting radiotracers. In conclusion, the DV1-k-(DV3) scaffold is a promising vector platform for translational CXCR4-directed research.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537445 | PMC |
| http://dx.doi.org/10.3390/pharmaceutics13101619 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ga-pentixafor PET/CT Is a Supplementary Method for Primary Aldosteronism Subtyping Compared with Adrenal Vein Sampling.
Mol Imaging Biol
December 2024
Department of Nuclearuclear Medicine, Peking University First Hospital, Beijing, China.
Purpose: To investigate the diagnostic efficacy of Ga-pentixafor positron emission tomography/computed tomography (PET/CT) in primary aldosteronism (PA) subtyping and lateralization of aldosterone secretion in PA patients.
Procedures: 37 patients who were diagnosed with PA, were prospectively enrolled in the study, and underwent adrenal vein sampling (AVS) after Ga-pentixafor PET/CT was conducted. Lateralization index (LI), defined as aldosterone/cortisol ratio in the dominant side to the contralateral adrenal vein when bilateral adrenal vein catheterization succeeded, and the aldosterone/cortisol ratio in the left adrenal vein to IVC (LAV/IVC) when the catheterization of right adrenal vein failed, were applied to determine lateralization side.
A Prospective Evaluation of Chemokine Receptor-4 (CXCR4) Overexpression in High-grade Glioma Using Ga-Pentixafor (Pars-Cixafor™) PET/CT Imaging.
Acad Radiol
December 2024
Division of Nuclear Medicine and Molecular Imaging, Department of Medical Imaging, Geneva University Hospital, CH-1211 Geneva 4, Switzerland (H.A., H.Z.); Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, Netherlands (H.Z.); Department of Nuclear Medicine, University of Southern Denmark, Odense, Denmark (H.Z.); University Research and Innovation Center, Óbuda University, Budapest, Hungary (H.Z.). Electronic address:
Background: While magnetic resonance imaging (MRI) remains the gold standard for morphological imaging, its ability to differentiate between tumor tissue and treatment-induced changes on the cellular level is insufficient. Notably, glioma cells, particularly glioblastoma multiforme (GBM), demonstrate overexpression of chemokine receptor-4 (CXCR4). This study aims to evaluate the feasibility of non-invasive Ga-Cixafor™ PET/CT as a tool to improve diagnostic accuracy in patients with high-grade glioma.
View Article and Find Full Text PDFDiagnostic Accuracy and Value of CXCR4-targeted PET/MRI Using Ga-Pentixafor for Tumor Localization in Cushing Disease.
Radiology
December 2024
From the Department of Radiology (Yue Wu, S.W., W.R., Z. Yao), Department of Neurosurgery, Shanghai Pituitary Tumor Center (B.Y., Z. Ye, R.H., N.Q., Y. Zhang, X.Y., Z.M., Y. Wang, Y. Zhao, Q.Z.), Department of Nuclear Medicine and PET Center (Yanfei Wu, S.R., Y.G., F.X.), and Department of Endocrinology (M.H., S.Z., Y.Y., H.Y., Z.Z.), Huashan Hospital, Fudan University, 12 Wulumuqi Road, Shanghai 200040, China; Neurosurgical Institute of Fudan University, Shanghai, China (B.Y., Z. Ye, R.H., N.Q., Y. Zhang, X.Y., Z.M., Y. Wang, Y. Zhao, Q.Z.); Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China (B.Y., Z. Ye, R.H., N.Q., Y. Zhang, X.Y., Z.M., Y. Wang, Y. Zhao, Q.Z.); Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shanghai, China (B.Y., Z. Ye, R.H., N.Q., Y. Zhang, X.Y., Z.M., Y. Wang, Y. Zhao, Q.Z.); and Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Neuroendocrine Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Mass (Q.Z.).
Background Gallium 68 (Ga) pentixafor has emerged as a potential C-X-C chemokine receptor type 4 (CXCR4)-targeted radiotracer for neuroendocrine tumor, yet its application in Cushing disease remains uncertain. Purpose To assess the diagnostic accuracy and value of Ga-pentixafor PET/MRI in localizing adrenocorticotropic hormone (ACTH)-secreting pituitary tumors in Cushing disease. Materials and Methods A prospective single-center study was conducted from March 2023 to February 2024 in participants with Cushing disease scheduled for surgical pituitary tumor resection.
View Article and Find Full Text PDFSelective PET imaging of CXCR4 using the AlF-labeled antagonist LY2510924.
Eur J Nucl Med Mol Imaging
December 2024
Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Background: [Ga]PentixaFor detects C-X-C chemokine receptor type 4 (CXCR4) overexpression in various malignancies, such as multiple myeloma and non-Hodgkin lymphomas, as well as in endocrine and inflammatory disorders. This study aimed to develop an AlF-labeled radiotracer derived from LY2510924 for CXCR4-targeted imaging, leveraging the physical and logistical advantages of fluorine-18.
Methods: We designed a CXCR4-specific radioprobe, [F]AlF-NOTA-SC, based on LY2510924 by incorporating a triglutamate linker and NOTA chelator to enable AlF-labeling.
An in vivo tumour organoid model based on the chick embryonic chorioallantoic membrane mimics key characteristics of the patient tissue: a proof-of-concept study.
EJNMMI Res
September 2024
Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
Article Synopsis
- Patient-derived tumour organoids (PDOs) were combined with the chorioallantoic membrane (CAM) of chicken eggs to create a vascularized model, aiming to study liver metastasis from colorectal cancer (CRC).
- The resulting xenografts showed high viability and vascularization, closely resembling the original patient's liver metastasis in both morphology and protein expression (CXCR4).
- Although the study observed [Ga]Ga-Pentixafor uptake in the CAM-PDXs, the results indicated no significant differences compared to initial PDOs, highlighting the potential for this model in translational cancer research.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!